Investigational — not available anywhere
This compound is not approved for any use and is not currently sold by any vendor, including research-chemical and RUO (“research use only”) sellers. Everything on this page comes from the developer’s own registered trials or from published research; there is no legitimate product to buy under this name, and any listing claiming otherwise should be treated with suspicion. See the full Obesity Pipeline for other compounds at this same stage.
UBT251 is an investigational injectable drug that activates three metabolic receptors at once, GLP-1, GIP, and glucagon, putting it in the same drug class as Eli Lilly’s retatrutide. It was developed in China by United Biotechnology, a subsidiary of The United Laboratories, which licensed the drug’s rights outside Greater China to Novo Nordisk in March 2025. In a 24-week phase 2 trial in Chinese adults with obesity, it produced up to 19.7% mean weight loss versus 2.0% with placebo. In a separate phase 2 trial in type 2 diabetes, it outperformed a head-to-head semaglutide 1 mg comparator on both blood sugar control and weight loss. It has never been approved and has never been legitimately sold anywhere.
Research snapshot
| Peptide category | GLP-1/GIP/glucagon receptor triple agonist |
| Primary research interest | Obesity and type 2 diabetes |
| Highest available evidence | Published Phase 1a/1b human trial; two separate Phase 2 trials with strong reported results (obesity and type 2 diabetes) |
| Human research available | Yes — Phase 1 published, two Phase 2 trials reported; China Phase 3 reportedly initiated per one industry database, not independently confirmed against a primary trial registry |
| Development status | Phase 2 completed in China (both obesity and type 2 diabetes); China Phase 3 planned or reportedly underway; Novo Nordisk’s global Phase 2 trial expected to start second half of 2026 |
| Regulatory status | Not approved anywhere. Not sold under any legitimate or grey-market channel. |
| Last reviewed | September 27, 2026 |
Technical identity
| Primary name | UBT251 |
| Alternative names | None identified beyond the code name itself |
| Peptide sequence | Not published in a source reviewed for this page |
| Amino-acid length | Not reliably established |
| Molecular formula | Not reliably established |
| Molecular weight | Not reliably established |
| CAS Registry Number | Not reliably established |
| PubChem CID | Not reliably established |
| UNII | Not reliably established |
| DrugBank ID | Not listed |
| Chemical modifications | Not disclosed in the sources reviewed |
| Peptide class | Multi-receptor (triple) incretin/glucagon agonist, same mechanistic class as retatrutide |
| Primary biological target | GLP-1 receptor, GIP receptor, and glucagon receptor (GCGR) |
| Developer or originator | The United Bio-Technology (Hengqin) Co., Ltd., a subsidiary of The United Laboratories International Holdings Limited; licensed outside Greater China to Novo Nordisk (agreement signed March 2025) |
| Development status | Phase 2 completed (China); Phase 3 reportedly initiated in China per one industry aggregator, not independently confirmed; global Phase 2 (Novo Nordisk) expected to begin in the second half of 2026 |
What is UBT251?
UBT251 belongs to the same drug class as Eli Lilly’s retatrutide: a “triple agonist” designed to activate three separate metabolic hormone receptors, GLP-1, GIP, and glucagon, in one molecule, on the theory that hitting all three pathways produces greater metabolic benefit than a single- or dual-receptor drug. It was developed in China by United Biotechnology, a subsidiary of The United Laboratories International Holdings Limited, and in March 2025 the company signed an exclusive licensing agreement giving Novo Nordisk worldwide development, manufacturing, and commercial rights everywhere except mainland China, Hong Kong, Macau, and Taiwan, a deal structure common for promising China-originated drugs being brought to global markets.
Unlike the other two new pipeline entries covered alongside it (NBIP-1968 and nisotirostide), UBT251 already has a meaningfully mature evidence base. Its phase 1a/1b safety and pharmacokinetics data has been published in a peer-reviewed journal (Diabetes, Obesity and Metabolism). It has completed two separate phase 2 trials in China: one in 205 adults with obesity or overweight, readout announced February 2026, and a second, larger head-to-head trial in 211 adults with type 2 diabetes that directly compared UBT251 against semaglutide 1 mg as well as placebo, readout announced shortly after. Both trials reported strong results, discussed in detail below.
As of this review, one industry pharma database lists UBT251’s highest global development phase as phase 3, with China phase 3 trials for type 2 diabetes, obesity, and obstructive sleep apnea; however, the primary press releases and trade-press coverage reviewed for this page, both from within the roughly seven months before this research pass, describe phase 3 as planned rather than already underway, and Novo Nordisk’s own global phase 2 trial, outside Greater China, is stated as not expected to begin until the second half of 2026. That discrepancy is stated plainly here rather than resolved by picking one figure and presenting it as settled.
How does it work?
Plain-English explanation
UBT251 works the same way as other “triple agonist” obesity drugs: it is designed to copy three separate hormone signals your body normally uses after eating, GLP-1, GIP, and glucagon, in a single weekly injection, aiming for a bigger combined effect on appetite, blood sugar, and metabolism than a drug that only targets one of those signals.
Technical explanation
UBT251 is a subcutaneously injected agonist at the GLP-1 receptor, the GIP receptor, and the glucagon receptor (GCGR), the same three-receptor mechanism as retatrutide, though the two molecules are chemically distinct and have not been directly compared in a published head-to-head trial. No detailed receptor-binding potency, pharmacokinetic half-life, or structural data from the published phase 1a/1b paper was independently re-extracted for this page, the full paper sits behind a subscription paywall that this review could not access; readers wanting those specifics should consult Yang et al., Diabetes, Obesity and Metabolism, cited below, directly.
Potential benefits and research applications
Weight loss in obesity and overweight
In the phase 2 trial (205 Chinese adults with obesity or overweight and at least one weight-related comorbidity, mean baseline weight 92.2 kg, mean baseline BMI 33.1), 24 weeks of once-weekly UBT251 at doses of 2 mg, 4 mg, or 6 mg produced up to 19.7% mean weight loss (-17.5 kg) versus 2.0% (-1.6 kg) with placebo. The trial also reported statistically significant improvements versus placebo in waist circumference, blood glucose, blood pressure, and lipids across all dose groups. The most common adverse events were gastrointestinal, described by the company as mostly mild to moderate and diminishing over time. Evidence: has been shown in a company-reported, congress/press-released phase 2 human trial; full peer-reviewed publication of this specific trial’s results was not identified as of this review.
Glycemic control and weight loss in type 2 diabetes, head-to-head against semaglutide
In a separate, larger phase 2 trial (211 Chinese adults with type 2 diabetes, mean baseline HbA1c 8.12%, managed on lifestyle alone or with metformin), UBT251 at the same three dose levels was compared directly against both placebo and semaglutide 1 mg over 24 weeks. UBT251’s highest-performing dose reduced HbA1c by up to 2.16%, versus 1.77% for semaglutide 1 mg and 0.66% for placebo. Weight loss was also greater with UBT251, up to 9.8%, than with semaglutide 1 mg, 4.8%, or placebo, 1.4%. The company described UBT251’s safety and tolerability profile in this trial as “consistent with what has been observed in other clinical trials with triple-G agonists,” a fairly candid way of saying it behaves like other drugs in this class rather than claiming an unusually clean profile. Evidence: has been shown in a company-reported, head-to-head phase 2 human trial; full peer-reviewed publication not identified as of this review. This is a genuinely direct comparison against an approved drug, which is a stronger form of evidence than a placebo-only trial, though it remains company-reported pending journal publication.
Safety and pharmacokinetics (phase 1a/1b)
A randomized, placebo-controlled phase 1a/1b study of UBT251 has been published in a peer-reviewed journal, establishing initial safety, pharmacokinetic, and pharmacodynamic data ahead of the phase 2 program. The full paper was not independently accessible for detailed extraction in this review. Evidence: has been shown in a published, peer-reviewed human clinical trial for the safety/PK/PD endpoints that paper covers specifically.
What dosage information circulates?
Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate. UBT251 has never been sold anywhere, legitimately or otherwise. Every dose used in human testing so far has been inside a sponsor-controlled trial.
The phase 1a/1b safety and pharmacokinetics study used ascending subcutaneous dose cohorts, both single and multiple ascending doses, but specific milligram amounts were not independently re-extracted from the paywalled full paper for this page. Both completed phase 2 trials, in obesity/overweight and in type 2 diabetes, tested subcutaneous doses of 2 mg, 4 mg, or 6 mg once weekly over 24 weeks (the diabetes trial also included a semaglutide 1 mg comparator arm). China phase 3 trials, whether already underway or still planned depending on the source, have not yet disclosed dose amounts.
UBT251 is unusual among this batch of new entries in that its phase 2 dose arms, 2 mg, 4 mg, 6 mg weekly, are actually public, disclosed in both the obesity and type 2 diabetes press releases, which is more dosing transparency than either NBIP-1968 or nisotirostide has offered so far. What is not public is which specific dose produced the headline 19.7% and 2.16% figures; both press releases describe those as the “highest mean” result across the tested doses without breaking out the per-arm numbers in the sources reviewed here. That is a meaningful gap for a reader trying to understand the actual dose-response relationship, and this page does not fill it in with a guess.
| Reported use or research objective | Route reported | Amount reported | Frequency reported | Reported duration | Evidence or source category |
|---|---|---|---|---|---|
| Phase 1a/1b safety and pharmacokinetics | Subcutaneous | Ascending dose cohorts; specific mg amounts not independently re-extracted from the paywalled full paper | Single and multiple ascending doses | Not independently confirmed | Published human clinical trial (Yang et al., DOM, 2026) |
| Phase 2, obesity/overweight | Subcutaneous | 2 mg, 4 mg, or 6 mg | Once weekly | 24 weeks | Company-reported Phase 2 human trial |
| Phase 2, type 2 diabetes, head-to-head vs semaglutide | Subcutaneous | 2 mg, 4 mg, or 6 mg (UBT251); semaglutide comparator arm at 1 mg | Once weekly | 24 weeks | Company-reported Phase 2 human trial |
| China Phase 3 (planned, or per one industry database, initiated) | Subcutaneous | Not yet disclosed | Once weekly (expected) | Not yet disclosed | Registered/planned human trial; currency of “initiated” status not independently confirmed |
| Practitioner or community protocols | — | — | — | — | Not consistently reported — no established or reliably sourced dosing information exists |
What circulates E5
| Reported use | Route | Amount reported | Frequency | Reported length |
|---|---|---|---|---|
| Phase 1a/1b safety and pharmacokinetics | Subcutaneous | Ascending dose cohorts; specific mg amounts not independently re-extracted from the paywalled full paper for this page | Single and multiple ascending doses | Not independently confirmed |
| Phase 2, obesity/overweight | Subcutaneous | 2 mg, 4 mg, or 6 mg | Once weekly | 24 weeks |
| Phase 2, type 2 diabetes, head-to-head vs. semaglutide | Subcutaneous | 2 mg, 4 mg, or 6 mg (UBT251); semaglutide comparator arm at 1 mg | Once weekly | 24 weeks |
| China phase 3 (planned or, per one industry database, initiated) | Subcutaneous | Not yet disclosed | Once weekly (expected) | Not yet disclosed |
| Community, forum, or vendor protocol | Not applicable | Not applicable; no established or reliably sourced dosing information exists | Not applicable | Not applicable |
No established or reliably sourced consumer dosing information was identified. UBT251 has never been sold anywhere, legitimately or otherwise; every dose used in human testing so far has been inside a sponsor-controlled trial, and UBT251 has no meaningful grey-market presence identified.
Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.
Side effects, risks, and limitations
Reported in the two phase 2 trials: gastrointestinal adverse events were the most common, described by the sponsor as mostly mild to moderate and diminishing over time in the obesity trial, and as “consistent with what has been observed in other clinical trials with triple-G agonists” in the diabetes trial, language that implies a typical GI-side-effect burden for this drug class rather than an unusually favorable or unfavorable one. Neither press release reviewed for this page broke out specific adverse-event rates, nausea, vomiting, diarrhea percentages, or discontinuation rates by dose arm.
What is not established: long-term safety beyond the 24-week trials completed so far; specific per-dose efficacy and safety breakdowns; and any data from Novo Nordisk’s own global trial program, which has not yet started as of the sources reviewed. Because UBT251 has never been sold outside sponsor-controlled trials, there is no purity, contamination, or counterfeit-product concern to report.
Regulatory and developmental status
UBT251 is not approved anywhere. It has completed phase 2 trials in China for both obesity/overweight and type 2 diabetes, with strong reported results in both, including a head-to-head comparison against semaglutide 1 mg. Per the primary press releases reviewed, dated within roughly the seven months before this research pass, Chinese phase 3 trials for type 2 diabetes were planned but not yet confirmed as started, and Novo Nordisk’s own global phase 2 trial, covering markets outside Greater China under its March 2025 licensing agreement, was expected to begin in the second half of 2026. One industry pharma database lists UBT251’s global development status as phase 3 across type 2 diabetes, obesity, and obstructive sleep apnea as of a more recent update; this page flags that as not independently confirmed against a primary trial registry or company announcement and recommends a status recheck before this page is treated as fully current.
Frequently asked questions
What is UBT251?
UBT251 is an investigational triple-receptor agonist, GLP-1, GIP, and glucagon, developed by China’s United Biotechnology and licensed to Novo Nordisk for markets outside Greater China, being studied for obesity and type 2 diabetes.
How does UBT251 work?
It activates three separate hormone receptors your body uses to regulate appetite, blood sugar, and metabolism, the same mechanistic strategy as Eli Lilly’s retatrutide, though the two drugs are chemically distinct.
What dosage has been studied?
Phase 2 trials tested 2 mg, 4 mg, and 6 mg once weekly by subcutaneous injection. The specific dose behind the headline results, 19.7% weight loss, 2.16% HbA1c reduction, was not broken out in the press releases reviewed.
What dosage commonly circulates online?
None. UBT251 has never been available for purchase anywhere; it exists only inside sponsor-controlled clinical trials.
Has UBT251 been studied in humans?
Yes, extensively for a compound this new: a published phase 1a/1b trial and two completed phase 2 trials, one in obesity and one in type 2 diabetes with a head-to-head semaglutide comparator.
Is UBT251 approved?
No. It is in phase 2-to-3 transition depending on the source, but not approved anywhere.
How does UBT251 compare to semaglutide?
In a direct head-to-head phase 2 trial, UBT251 outperformed semaglutide 1 mg on both HbA1c reduction, 2.16% vs. 1.77%, and weight loss, 9.8% vs. 4.8%, over 24 weeks.
How does UBT251 compare to retatrutide?
Both are GLP-1/GIP/glucagon triple agonists, but they have not been tested head-to-head, and UBT251’s data comes from a shorter 24-week window versus retatrutide’s longer published trials, so a direct efficacy comparison is not straightforward from the public data alone.
What remains unknown?
The specific dose behind the top-line results, detailed adverse-event and discontinuation rates, whether China phase 3 trials have actually started, sources disagree, and any data from Novo Nordisk’s planned global trial program.
Bottom line
UBT251 is arguably the strongest new pipeline candidate in this batch of three: it already has a published phase 1 safety paper and two solid phase 2 readouts, including a genuinely head-to-head win against semaglutide 1 mg on both blood sugar and weight. Novo Nordisk’s March 2025 licensing deal signals real confidence in the molecule from a company that knows this space better than almost anyone. That said, one real loose end has to be flagged: sources disagree on whether China phase 3 trials have already started or are merely planned, and Novo Nordisk’s own global program has not begun. It has never been approved and has never been sold anywhere, and per-dose efficacy and safety detail beyond the topline numbers is not public yet.